Selegiline: a molecule with innovative potential

Monoamine oxidase B (MAO-B) inhibitors have an established role in the treatment of Parkinson’s disease as monotherapy or adjuvant to levodopa. Two major recognitions were required for their introduction into this therapeutic field. The first was the elucidation of the novel pharmacological properti...

Descripción completa

Detalles Bibliográficos
Autores principales: Tábi, Tamás, Vécsei, László, Youdim, Moussa B., Riederer, Peter, Szökő, Éva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2019
Materias:
Neurology and Preclinical Neurological Studies - Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242272/
https://www.ncbi.nlm.nih.gov/pubmed/31562557
http://dx.doi.org/10.1007/s00702-019-02082-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242272/
https://www.ncbi.nlm.nih.gov/pubmed/31562557
http://dx.doi.org/10.1007/s00702-019-02082-0

Ejemplares similares